Mikkelsen-Lopez Inez, Shango Winna, Barrington Jim, Ziegler Rene, Smith Tom, deSavigny Don
Swiss Tropical and Public Health Institute, Basel, Switzerland.
Malar J. 2014 May 11;13:181. doi: 10.1186/1475-2875-13-181.
Between 2007 and 2013, the Tanzanian public sector received 93.1 million doses of first-line anti-malarial artemisinin-based combination therapy (ACT) in the form of artemether-lumefantrine entirely supplied by funding partners. The introduction of a health facility ACT stock monitoring system using SMS technology by the National Malaria Control Programme in mid 2011 revealed a high frequency of stock-outs of ACT in primary care public health facilities. The objective of this study was to determine the pattern of availability of ACT and possible causes of observed stock-outs across public health facilities in Tanzania since mid-2011.
Data were collected weekly by the mobile phone reporting tool SMS for Life on ACT availability from over 5,000 public health facilities in Tanzania starting from September 2011 to December 2012. Stock data for all four age-dose levels of ACT across health facilities were summarized and supply of ACT at the national level was also documented.
Over the period of 15 months, on average 29% of health facilities in Tanzania were completely stocked out of all four-age dose levels of the first-line anti-malarial with a median duration of total stock-out of six weeks. Patterns of total stock-out by region ranged from a low of 9% to a high of 52%. The ACT stock-outs were most likely caused by: a) insufficient ACT supplies entering Tanzania (e.g. in 2012 Tanzania received 10.9 million ACT doses compared with a forecast demand of 14.4 million doses); and b) irregular pattern of ACT supply (several months with no ACT stock).
The reduced ACT availability and irregular pattern of supply were due to cumbersome bureaucratic processes and delays both within the country and from the main donor, the Global Fund to Fight AIDS, Tuberculosis and Malaria. Tanzania should invest in strengthening both the supply system and the health information system using mHealth solutions such as SMS for Life. This will continue to assist in tracking ACT availability across the country where all partners work towards more streamlined, demand driven and accountable procurement and supply chain systems.
2007年至2013年期间,坦桑尼亚公共部门收到了9310万剂一线抗疟青蒿素联合疗法(ACT),其形式为蒿甲醚-本芴醇,全部由资助伙伴提供。2011年年中,国家疟疾控制计划采用短信技术引入了医疗机构ACT库存监测系统,结果显示初级保健公共卫生设施中ACT缺货的频率很高。本研究的目的是确定自2011年年中以来坦桑尼亚公共卫生设施中ACT的可获得模式以及观察到的缺货的可能原因。
从2011年9月至2012年12月,通过手机报告工具“生命短信”每周收集坦桑尼亚5000多个公共卫生设施中ACT可获得性的数据。汇总了各卫生设施所有四种年龄剂量水平ACT的库存数据,并记录了国家层面的ACT供应情况。
在15个月的时间里,坦桑尼亚平均有29%的卫生设施所有四种年龄剂量水平的一线抗疟药物完全缺货,总缺货的中位持续时间为六周。各地区的总缺货模式从低至9%到高至52%不等。ACT缺货最有可能是由以下原因导致的:a)进入坦桑尼亚的ACT供应不足(例如,2012年坦桑尼亚收到1090万剂ACT,而预测需求为1440万剂);b)ACT供应模式不规律(有几个月没有ACT库存)。
ACT可获得性降低和供应模式不规律是由于国内以及主要捐助方全球抗击艾滋病、结核病和疟疾基金繁琐的官僚程序和延误造成的。坦桑尼亚应投资加强供应系统和卫生信息系统,采用诸如“生命短信”之类的移动健康解决方案。这将继续有助于跟踪全国范围内的ACT可获得情况,所有伙伴都朝着更精简、需求驱动和可问责的采购及供应链系统努力。